Abbott Laboratories: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025 · 2025 vs 2024
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
5
Modified
15
Unchanged
🟢 New in Current Filing Adverse changes in tax laws, regulations and interpretations, both in the U.S. and internationally, could have a material adverse effect on Abbott’s effective tax rate, financial condition and results of operations. 🔒
🟡 Modified Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the COVID-19 pandemic, which had a material effect on Abbott’s business, financial condition and results of operations. 🔒
🟡 Modified Disruptions to Abbott’s global supply chain, which is large and complex, could negatively affect Abbott’s results of operations. 🔒
🟡 Modified Abbott depends on sophisticated information systems and maintains protected personal data, and a significant cybersecurity incident or other disruption affecting these information systems or protected data could have a material adverse effect on Abbott’s business, financial condition and results of operations. 🔒
🟡 Modified It is costly for Abbott to comply with numerous governmental regulations and to develop compliant products and processes, and consequences for non-compliance could have a material adverse effect on Abbott's revenues, profitability, cash flows, and financial condition. 🔒
🟡 Modified New products and technological advances by Abbott’s competitors may negatively affect Abbott’s results of operations. 🔒
6 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →